表紙
市場調査レポート

EpiCast Report:多発性骨髄腫の疫学的予測 2023年

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023

発行 GlobalData 商品コード 336858
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
EpiCast Report:多発性骨髄腫の疫学的予測 2023年 EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023
出版日: 2015年10月05日 ページ情報: 英文 43 Pages
概要

世界の主要8市場 (米国・フランス・ドイツ・イタリア・スペイン・英国・日本・中国都市部) における多発性骨髄腫 (MM) の診断症例数は、2013年から2023年にかけて4.39%の年成長率で推移し、2013年の6万7,557件から2023年には9万7,225件に達すると予測されています。

当レポートでは、世界の主要8市場における多発性骨髄腫 (MM) の診断症例数および死亡者数の推移について調査し、疾患の背景、リスク要因と併存症、年齢・性別・重篤度・原因病原別の診断症例数および死亡者数の予測などについてまとめています。

第1章 目次

第2章 イントロダクション

第3章 疫学

  • 疾患の背景
  • リスク要因と併存症
  • 世界の動向
    • 発症率
    • 多発性骨髄腫 (MM) の生存率:主要8市場
  • 予測手法
    • 使用ソース
    • 未使用ソース
    • 予測の前提条件・手法:多発性骨髄腫 (MM) の診断症例
    • 予測の前提条件・手法:多発性骨髄腫 (MM) の5年間の有病診断症例
    • 予測の前提条件・手法:多発性骨髄腫 (MM) 診断時の臨床病期
  • 多発性骨髄腫 (MM) の疫学的予測
    • 診断症例数
    • 診断症例数:年齢別
    • 診断症例数:性別
    • 標準診断事例数:年齢別
    • 診断時の臨床病期
    • 5年間の有病診断症例数
  • 検証
    • 疫学的予測の考察
    • 分析の限界
    • 分析の強み

第4章 付録

  • 参考資料
  • 著者について
  • GlobalDataについて
  • EpiCastについて
  • 免責事項

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHCER083-15

Multiple myeloma is a hematologic cancer of the white blood cell; more specifically, multiple myeloma is a cancer of the plasma cell. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but multiple myeloma causes cancer cells to accumulate in the bone marrow where they crowd out healthy blood cells, impairing their ability to fight infections. Rather than producing helpful antibodies, the cancer cells produce abnormal proteins called monoclonal (M) proteins that can impair kidney functions.

GlobalData epidemiologists forecast the diagnosed incident and five-year diagnosed prevalent cases of multiple myeloma in the 8MM. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of multiple myeloma in the 8MM, from 67,557 diagnosed incident cases in 2013 to 97,225 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 4.39% during the forecast period. The five-year diagnosed prevalent cases of multiple myeloma in the 8MM are expected to increase from 168,750 diagnosed prevalent cases in 2013 to 236,866 diagnosed prevalent cases in 2023, with an AGR of 4.04% during the forecast period. The increase in the diagnosed five-year prevalent cases of multiple myeloma is partly attributed to the moderately rising trend in the incidence of multiple myeloma in the 8MM, combined with changes in the population demographics in the respective markets.

GlobalData's forecast is supported by at least 10 years of robust, country-specific historical data obtained from the WHO International Agency for Cancer Research's (IARC's) SurvCan, the Surveillance of Epidemiology and End Results Program Cancer Statistics Review 1975-2009, EUROCARE-4, research articles published in peer-reviewed journals, and the IARC's Cancer Incidence in Five Continents Plus database, which provided detailed case segmentation by age and sex and is considered the gold standard for international comparison of country-specific data. Another strength of this analysis is that GlobalData epidemiologists compared the incident case projections with the estimates made by country-specific registries and the IARC, and found that the forecast numbers were in accordance with the international estimates.

Scope

  • The Multiple Myleoma EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for multiple myeloma in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). The series includes a 10-year epidemiological forecast for diagnosed incident and total prevalent cases of monoclonal gammopathy of undetermined significance (MGUS) cases, segmented by age and sex. It also includes a 10-year forecast for diagnosed incident cases of multiple myeloma, segmented by age (in five-year increments beginning at 40 years and ending at =85 years), sex, and stage at clinical diagnosis, as well as a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of multiple myeloma in these markets.
  • The Multiple Myeloma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Multiple Myeloma EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global multiple myeloma market.
  • Quantify patient populations in the global multiple myeloma market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for multiple myeloma therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. 4.3.1 Incidence
    • 3.3.2. Survival Rates for MM - 8MM
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods, MM Diagnosed Incident Cases
    • 3.4.4. Forecast Assumptions and Methods, MM Five-Year Diagnosed Prevalent Cases
    • 3.4.5. Forecast Assumptions and Methods, MM Clinical Stages at Diagnosis
  • 3.5. Epidemiological Forecast for MM (2013-2023)
    • 3.5.1. Diagnosed Incident Cases of MM
    • 3.5.2. Age-Specific Diagnosed Incident Cases of MM
    • 3.5.3. Sex-Specific Diagnosed Incident Cases of MM
    • 3.5.4. Age-Standardized Diagnosed Incidence of MM
    • 3.5.5. Diagnosed Incident Cases of MM by Clinical Stage at Diagnosis
    • 3.5.6. Five-Year Diagnosed Prevalent Cases of MM
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: MM Clinical Stages at Diagnosis, Using the ISS Criteria
  • Table 2: Risk Factors and Comorbidities for MM
  • Table 3: Trends in the Age-Adjusted Incidence of MM in the US, Ages ≥40 Years, 1993-2007
  • Table 4: Trends in the Age-Adjusted Incidence of MM in the 5EU, Ages ≥40 Years, 1993-2007
  • Table 5: Trends in the Age-Adjusted Incidence of MM in Japan, Ages ≥40 Years, 1993-2007
  • Table 6: Trends in the Age-Adjusted Incidence of MM in Urban China, Ages ≥40 Years, 1993-2007
  • Table 7: Trends in the Five-Year Relative Survival (%) of MM in the 8MM, Both Sexes, 1993-2009
  • Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast for MM Diagnosed Incident Cases
  • Table 9: 8MM, Sources of Epidemiological Data Used for the Forecast for MM Diagnosed Five-Year Prevalent Cases
  • Table 10: 8MM, Sources of Epidemiological Data Used for the Segmentation of MM Incident Cases by Clinical Stage at Diagnosis
  • Table 11: 8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Table 12: 8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, N (Row %), 2013
  • Table 13: 8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages ≥40 Years, N (Row %), 2013
  • Table 14: 8MM, Five-Year Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023
  • Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, N, 2013
  • Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages ≥40 Years, N, 2013
  • Figure 4: 8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Ages ≥40 Years, by Sex, 2013
  • Figure 5: 8MM, Diagnosed Incident Cases of MM by Clinical Stage at Diagnosis, Ages ≥40 Years, N, 2013
  • Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023
Back to Top